Trevena Inc
Laatste artikelen op Beursig.com
Beleggen in bitcoin en ethereum op Euronext beurs
Wild west taferelen bij aandelen, crypto valuta en ...
Volg Beursig.com
-
piddybull
- waarderingen: 2
-
piddybull
- waarderingen: 2
Re: Trevena Inc
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
December 10, 2020 8:43am EST
--
Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy
TRV045 selectively targets the S1P1 receptor without associated lymphopenia
IND filing on track for 1H 2021
--
CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference was held virtually from December 6th to 9th, 2020.
The presentations included two posters, both of which discussed the potential utility of TRV045 to treat a variety of CNS disorders, including epilepsy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy (DPN). The Company is currently collaborating with the National Institutes of Health (NIH) to evaluate TRV045 in their screening programs for epilepsy and non-addictive treatment of pain.
“These are compelling nonclinical findings for TRV045 and support its potential application in the treatment of epilepsy and neuropathic pain. We look forward to continuing to investigate the potential of TRV045 as a treatment for these debilitating disorders,” said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc.
Poster Details
“TRV045, a novel, selective S1PR1 modulator, is efficacious in reversing neuropathic pain without affecting lymphocyte trafficking” (Poster #T125)
TRV045 demonstrated efficacy comparable to fingolimod, an approved S1P receptor modulator, in a mouse CIPN model. Unlike fingolimod, TRV045 did not cause lymphopenia at therapeutic doses.
TRV045 demonstrated efficacy comparable to gabapentin, an approved anticonvulsant medication sometimes used to treat diabetic neuropathy, in a rat diabetic peripheral neuropathy model. The Company believes this is the first time that modulation of the S1P1 receptor has been shown to have potential therapeutic benefit in reversing diabetic neuropathic pain.
“TRV045, a novel, selective S1P1 receptor modulator that is not an immunosuppressant, is efficacious in rodent models of epilepsy” (Poster #W105)
TRV045 was evaluated as a potential anti-epileptic treatment in four well-established rodent seizure models, as part of the NIH’s Epilepsy Therapy Screening Program (ETSP).
TRV045 demonstrated a dose-dependent seizure prevention response in three of the models.
TRV045 does not cause lymphopenia at therapeutic doses, suggesting it may offer unique therapeutic benefits in a variety of CNS indications, including epilepsy, where immunosuppression is not desirable. Notably, fingolimod has also shown efficacy in rodent epilepsy models, but with substantial immunosuppression.
All posters can be found at https://www.trevena.com/publications.
About TRV045
Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders. S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. TRV045 is a preclinical, investigational drug candidate that engages the S1P receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of neuropathic pain, TRV045 demonstrated activity with no lymphopenia at therapeutic doses. The National Institutes of Health are currently evaluating TRV045 as a potential treatment for epilepsy and as a potential non-addictive treatment for acute / chronic pain.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
December 10, 2020 8:43am EST
--
Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy
TRV045 selectively targets the S1P1 receptor without associated lymphopenia
IND filing on track for 1H 2021
--
CHESTERBROOK, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at the 59th Annual Meeting for the American College of Neuropsychopharmacology (ACNP). The conference was held virtually from December 6th to 9th, 2020.
The presentations included two posters, both of which discussed the potential utility of TRV045 to treat a variety of CNS disorders, including epilepsy, chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy (DPN). The Company is currently collaborating with the National Institutes of Health (NIH) to evaluate TRV045 in their screening programs for epilepsy and non-addictive treatment of pain.
“These are compelling nonclinical findings for TRV045 and support its potential application in the treatment of epilepsy and neuropathic pain. We look forward to continuing to investigate the potential of TRV045 as a treatment for these debilitating disorders,” said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc.
Poster Details
“TRV045, a novel, selective S1PR1 modulator, is efficacious in reversing neuropathic pain without affecting lymphocyte trafficking” (Poster #T125)
TRV045 demonstrated efficacy comparable to fingolimod, an approved S1P receptor modulator, in a mouse CIPN model. Unlike fingolimod, TRV045 did not cause lymphopenia at therapeutic doses.
TRV045 demonstrated efficacy comparable to gabapentin, an approved anticonvulsant medication sometimes used to treat diabetic neuropathy, in a rat diabetic peripheral neuropathy model. The Company believes this is the first time that modulation of the S1P1 receptor has been shown to have potential therapeutic benefit in reversing diabetic neuropathic pain.
“TRV045, a novel, selective S1P1 receptor modulator that is not an immunosuppressant, is efficacious in rodent models of epilepsy” (Poster #W105)
TRV045 was evaluated as a potential anti-epileptic treatment in four well-established rodent seizure models, as part of the NIH’s Epilepsy Therapy Screening Program (ETSP).
TRV045 demonstrated a dose-dependent seizure prevention response in three of the models.
TRV045 does not cause lymphopenia at therapeutic doses, suggesting it may offer unique therapeutic benefits in a variety of CNS indications, including epilepsy, where immunosuppression is not desirable. Notably, fingolimod has also shown efficacy in rodent epilepsy models, but with substantial immunosuppression.
All posters can be found at https://www.trevena.com/publications.
About TRV045
Trevena is currently developing a novel sphingosine-1-phosphate (S1P) receptor modulator, TRV045, as a non-opioid treatment for various CNS disorders. S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. TRV045 is a preclinical, investigational drug candidate that engages the S1P receptor in a more selective manner that does not produce immunosuppression or alter lymphocyte trafficking. In a preclinical model of neuropathic pain, TRV045 demonstrated activity with no lymphopenia at therapeutic doses. The National Institutes of Health are currently evaluating TRV045 as a potential treatment for epilepsy and as a potential non-addictive treatment for acute / chronic pain.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
Re: Trevena Inc
Wat zijn je verwachtingen op LT? Een artikel van september spreekt van $5 koersdoel en aardige verkoopcijfers tegen 2025.
"Everyone has the brainpower to make money in stocks. Not everyone has the stomach.”
-
piddybull
- waarderingen: 2
Re: Trevena Inc
Sebbie,
Ik volg dit aandeel al een tweetal jaren over de rug van een familielid.
Er zijn hoge verwachtingen maar buiten dat er al een product werd goedgekeurd is het wel een speelvogel geweest van veel en grote shortpartijen.
Toen ik onlangs vernam dat die shorts flink in aantal waren geslonken besloot ik aan te kopen.
Ikzelf vind me voor dit aandeel onbekwaam om koersdoelen te verrechtvaardigen.
Maar ik heb wel een patent op het getal 696 dus $ 6,96 moet kunnen als het product Olinvyk goed en breed verkocht kan worden op de Amerikaanse markt.
Een overname zou het aandeel wel vleugels kunnen geven maar dat is standaard toepasbaar voor elk aandeel.
Mocht je de tekst over uw bemerkingen kunnen posten dan zou dit fijn zijn.
Ik volg dit aandeel al een tweetal jaren over de rug van een familielid.
Er zijn hoge verwachtingen maar buiten dat er al een product werd goedgekeurd is het wel een speelvogel geweest van veel en grote shortpartijen.
Toen ik onlangs vernam dat die shorts flink in aantal waren geslonken besloot ik aan te kopen.
Ikzelf vind me voor dit aandeel onbekwaam om koersdoelen te verrechtvaardigen.
Maar ik heb wel een patent op het getal 696 dus $ 6,96 moet kunnen als het product Olinvyk goed en breed verkocht kan worden op de Amerikaanse markt.
Een overname zou het aandeel wel vleugels kunnen geven maar dat is standaard toepasbaar voor elk aandeel.
Mocht je de tekst over uw bemerkingen kunnen posten dan zou dit fijn zijn.
-
piddybull
- waarderingen: 2
-
piddybull
- waarderingen: 2
Re: Trevena Inc
H.C. Wainwright Keeps a Buy Rating on Trevena (TRVN)
Brian Anderson- November 3, 2020,
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Trevena (TRVN), with a price target of $5.00. The company’s shares closed last Monday at $2.69.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 10.9% and a 50.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevena with a $5.25 average price target.
Based on Trevena’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.22 million. In comparison, last year the company had a GAAP net loss of $4.69 million.
Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Brian Anderson- November 3, 2020,
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Trevena (TRVN), with a price target of $5.00. The company’s shares closed last Monday at $2.69.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 10.9% and a 50.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevena with a $5.25 average price target.
Based on Trevena’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.22 million. In comparison, last year the company had a GAAP net loss of $4.69 million.
Trevena, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
